Portfolio Forensic Audit Summary
NicHealth / Nicholas Investment Partners LP
Nine-Position Lookback — April 2026
Investor: Lisa Wheatley · 13F CIK 0001389574 · Audited: 04-27-2026 · 9 Positions Audited
~$150M
Active Portfolio Value
7
Kill Conditions on Watch
3
Binary Events in 90 Days
Full Portfolio — Audit Status
| # |
Ticker |
Drug |
Indication |
Entry |
Size |
Status |
Conf. |
Verdict |
Audit |
| 1 |
BBIO |
Acoramidis (Attruby) |
ATTR Cardiomyopathy |
Q2 2021 |
$21.8M |
Approved |
High |
Hold — Commercial execution. Audit said restructure at entry — correctly named enterprise risk (–85% drawdown). |
→ Audit #1 |
| 2 |
KRYS |
B-VEC (Vyjuvek) |
Dystrophic EB |
Q1 2023 (exit Q2 2023) |
— |
Exited |
High |
Exited at FDA approval. Cleanest chain in series — audit confirmed conviction. Perfect positive control. |
→ Audit #2 |
| 3 |
INSM |
Brensocatib (Brinsupri) |
Non-CF Bronchiectasis |
Q3 2025 |
$31.4M |
Approved |
High |
Hold — Commercial execution. Science de-risked. Largest position. Bet is payer access + diagnosis expansion. |
→ Audit #3 |
| 4 |
RVMD |
RMC-6236 (Daraxonrasib) |
KRAS-mutant solid tumors |
Q4 2025 |
$25.3M |
Pre-Ph3 |
Medium |
Proceed — Binary bet. Mechanism validated, BTD granted. ORR → OS in PDAC is the open link. |
→ Audit #4 |
| 5 |
ABVX |
Obefazimod |
Ulcerative Colitis |
Q4 2025 |
$11.2M |
Pre-data |
Medium |
Proceed — Maintenance binary. Induction positive. Smallest position consistent with binary risk. Q2 2026 resolution. |
→ Audit #5 |
| 6 |
NUVL |
Zidesamtinib |
ROS1+ NSCLC |
Q4 2025 |
$16.1M |
Pre-PDUFA |
High |
Proceed — Cleanest pre-approval chain. NDA accepted, no AdCom. PDUFA September 18, 2026. |
→ Audit #6 |
| 7 |
XENE |
XEN1101 |
Focal Epilepsy |
Q4 2025 |
$10.9M |
Pre-Ph3 |
High (Ph2b) |
Proceed — Largest single-quarter add. Kv7 class rehabilitation. Pigmentation monitoring is non-negotiable kill condition. |
→ Audit #7 |
| 8 |
MIRM |
Maralixibat (Livmarli) |
Cholestatic liver disease |
Pre-Q4 2025 |
$16.9M |
Approved |
High / Med (EXPAND) |
Hold — Commercial + unconfirmed pipeline optionality. EXPAND biliary atresia data 2027. |
→ Audit #8 |
| 9 |
AXSM |
Auvelity (AXS-05) |
MDD + Alzheimer's agitation |
Q4 2025 |
$16.7M |
PDUFA Apr 30 |
High (MDD) / Med (AD) |
Hold — Pre-PDUFA binary. Resolution in 2 days. Safety in elderly population is the CRL scenario. |
→ Audit #9 |
Catalyst Calendar — Ordered by Urgency
Apr 30, 2026
AXSM
Alzheimer's agitation NDA PDUFA — FDA decision on Auvelity's second indication. Binary event the Q4 2025 add was constructed around. ACCORD Phase 3 positive; safety in elderly population is the CRL risk.
Watch — 2 Days
Q2 2026
ABVX
Phase 3 maintenance remission data — the single most important unresolved question in the obefazimod thesis. Induction is positive. Maintenance is the binary that determines commercial viability.
Watch — Weeks
May 2026
INSM
Q1 2026 earnings — first full commercial quarter for Brinsupri. Year 1 annualized revenue pace vs. $150M kill condition benchmark. Payer coverage % and new prescription trends are the key read-throughs.
Watch — Revenue
May 2026
BBIO
Q1 2026 earnings — Attruby commercial ramp. Competing with tafamidis for ATTR-CM prescribers. Payer formulary access and superiority data adoption by cardiologists are the key metrics.
Intact
H2 2026
RVMD
RASolute 302 Phase 3 top-line OS data — KRAS-mutant NSCLC/PDAC. Thesis-defining event. No partial credit in PDAC survival trials. Enrollment complete as of entry period.
Intact — Pending
Sep 18, 2026
NUVL
Zidesamtinib PDUFA — ROS1+ NSCLC. NDA accepted without AdCom. Cleanest pre-approval chain in the portfolio. CRL probability is low; approval is the base case.
Intact — On Track
2027 (est.)
XENE
Phase 3 X-TOLE2 / X-TOLE3 top-line data — focal epilepsy. Phase 3 enrolling. Pigmentation safety at longer exposure durations is the monitored kill condition that overrides efficacy.
Intact — Enrolling
2027 (est.)
MIRM
EXPAND Phase 3 top-line data — biliary atresia and additional rare cholestatic diseases. Enrollment completed March 2026. Biliary atresia's obstructive pathophysiology makes this an extrapolation bet.
Intact — Enrolled
Kill Condition Watch List — Elevated Risk Items
AXSM — Critical — 2 Days
FDA issues Complete Response Letter for Alzheimer's agitation NDA.
PDUFA April 30, 2026. ACCORD Phase 3 was positive (NEJM 2024) and NDA was accepted without AdCom — both positive signals. CRL risk centers on elderly population safety: bupropion seizure risk and DXM falls risk in Alzheimer's patients were not fully characterized in ACCORD (n=178). A CRL does not kill the MDD franchise but removes the primary catalyst behind the Q4 2025 position add.
ABVX — Critical — Q2 2026
Phase 3 maintenance trial fails to show statistically significant sustained remission at 52 weeks.
Maintenance data is imminent. This is the single open question that determines whether obefazimod is commercially viable vs. established biologics (vedolizumab, ustekinumab). Induction success does not guarantee maintenance success. If maintenance fails, the drug may be approvable as induction-only, but commercial differentiation collapses. Position is sized appropriately ($11.2M, smallest major position).
INSM — Watch — Q1 2026 Earnings
Year 1 net revenue materially below $150M US annualized — signals diagnosis expansion and formulary access are gated.
Brinsupri launched August 2025. Q1 2026 is the first full commercial quarter. The commercial model depends on diagnosis expansion in a systematically underdiagnosed population (~70% undiagnosed). Payer coverage velocity is the leading indicator. Major payer restrictions (step-edit after antibiotic failure) would compress the addressable market by 40–60%.
XENE — Monitor Continuously — Non-Negotiable
Pigmentation signal (skin, ocular, mucosal) in Phase 3 long-term safety data.
Ezogabine (prior Kv7 opener, same class) was withdrawn 2017 for pigmentation — not efficacy failure. XEN1101 structurally avoids the responsible aromatic ring system. No signals in Phase 2b. But Phase 3 duration (longer) and scale (larger n) is the first definitive test. Even a single attributable pigmentation case triggers immediate reassessment. This is the kill condition that overrides any efficacy outcome.
NUVL — Monitor — Competitor Timeline
Taletrectinib (Roche) receives FDA approval for G2032R-resistant ROS1+ NSCLC before zidesamtinib's September 2026 PDUFA.
Taletrectinib is a competitor addressing the same G2032R resistance mechanism in ROS1+ NSCLC. If Roche achieves approval before September 2026, zidesamtinib loses first-mover advantage in the resistance setting. Zidesamtinib's data (ORR 44%, CNS ORR 56%) is strong — but label timing matters commercially in a small patient population.
RVMD — Monitor — Phase 3 Scale Safety
Dose-limiting toxicity from wild-type RAS inhibition emerges at Phase 3 population scale.
Daraxonrasib inhibits all RAS isoforms in the GTP-bound state — including wild-type RAS in normal tissue. Phase 1/2 (smaller n) showed manageable safety. Phase 3 (n=~400+) is the first large-scale exposure. If off-target wild-type RAS toxicity requires dose reduction that compromises efficacy, the therapeutic window collapses. This is the highest-concern safety risk in the platform mechanism.
MIRM — Monitor — Commercial Concentration
Maralixibat commercial ramp in ALGS/PFIC materially disappoints — small orphan patient population creates concentrated per-patient revenue risk.
ALGS and PFIC are ultra-rare diseases — a few hundred to a few thousand patients each in the US. Per-patient revenue is high but the population ceiling is real. Odevixibat (Bylvay, Albireo/Ipsen) is an approved competitor in PFIC and is pursuing ALGS label expansion. Competitive displacement in the approved indications would impair the commercial story independently of EXPAND outcome.
Portfolio Construction — What the Audits Reveal Collectively
Across nine positions, three structural patterns emerge from the forensic audit series. First, NicHealth's largest positions are the de-risked ones: INSM ($31.4M) and RVMD ($25.3M) — one post-approval commercial bet, one post-BTD-designation pre-Phase 3 bet with validated mechanism. The smallest major position (ABVX, $11.2M) carries the highest near-term binary risk. The sizing is not random — it appears calibrated to the audit's risk assessment even if implicitly.
Second, five of the nine positions are in drugs that have reached FDA approval or NDA submission. This is not a pre-clinical risk portfolio. The dominant risk is commercial execution and pipeline expansion, not mechanism validation. The forensic audit's job for this portfolio is primarily to clarify which chapter each position is in — not to discover hidden science failures.
Third, three binary events resolve in the next 90 days: AXSM (April 30), ABVX (Q2 2026), INSM Q1 revenue (May 2026). The portfolio's near-term risk is concentrated in a very short window. Whatever happens in Q2 2026 will reshape the portfolio's risk profile significantly.